Oral calcitriol and calcium

Efficient therapy for uremic hyperparathyroidism

Leigh Quarles, G. A. Davidai, S. J. Schwab, D. W. Bartholomay, B. Lobaugh

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Therapy with orally administered calcitriol often does not adequately control the biochemical manifestations of secondary hyperparathyroidism in uremic patients. This may be due to inadequate serum concentrations of 1,25(OH)2 vitamin D and/or to insufficient dietary calcium supplementation. In the present study, therefore, we examined the effect on parathyroid function of calcitriol and calcium carbonate, administered orally, in doses sufficient to normalize the serum 1,25(OH)2 vitamin D and calcium concentrations. After nine months of combined therapy, marked suppression of immunoreactive PTH occurred in the absence of hypercalcemia. Furthermore, prolonged therapy resulted in additional suppression of the PTH concentrations comparable in magnitude to that reported following intravenous calcitriol therapy and was associated with a mild degree of hypercalcemia similar to that which occurs with intravenous therapy. Euparathyroidism was achieved in 25% of the patients by 15 months of treatment. In conclusion, secondary hyperparathyroidism can be effectively controlled with combined oral therapy without significant hypercalcemia in selected patients with end-stage renal failure. This salutary effect may result from direct actions of 1,25(OH)2D on the parathyroid gland and/or gastrointestinal tract, or from an overall action of combined treatment to restore calcium homeostasis.

Original languageEnglish (US)
Pages (from-to)840-844
Number of pages5
JournalKidney International
Volume34
Issue number6
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Hyperparathyroidism
Calcitriol
Calcium
Hypercalcemia
Ergocalciferols
Secondary Hyperparathyroidism
Therapeutics
Dietary Calcium
Parathyroid Glands
Calcium Carbonate
Dietary Supplements
Serum
Chronic Kidney Failure
Gastrointestinal Tract
Homeostasis

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Oral calcitriol and calcium : Efficient therapy for uremic hyperparathyroidism. / Quarles, Leigh; Davidai, G. A.; Schwab, S. J.; Bartholomay, D. W.; Lobaugh, B.

In: Kidney International, Vol. 34, No. 6, 01.01.1988, p. 840-844.

Research output: Contribution to journalArticle

Quarles, L, Davidai, GA, Schwab, SJ, Bartholomay, DW & Lobaugh, B 1988, 'Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism', Kidney International, vol. 34, no. 6, pp. 840-844. https://doi.org/10.1038/ki.1988.258
Quarles, Leigh ; Davidai, G. A. ; Schwab, S. J. ; Bartholomay, D. W. ; Lobaugh, B. / Oral calcitriol and calcium : Efficient therapy for uremic hyperparathyroidism. In: Kidney International. 1988 ; Vol. 34, No. 6. pp. 840-844.
@article{644e7f29c3e646b0ba419e278aebaf18,
title = "Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism",
abstract = "Therapy with orally administered calcitriol often does not adequately control the biochemical manifestations of secondary hyperparathyroidism in uremic patients. This may be due to inadequate serum concentrations of 1,25(OH)2 vitamin D and/or to insufficient dietary calcium supplementation. In the present study, therefore, we examined the effect on parathyroid function of calcitriol and calcium carbonate, administered orally, in doses sufficient to normalize the serum 1,25(OH)2 vitamin D and calcium concentrations. After nine months of combined therapy, marked suppression of immunoreactive PTH occurred in the absence of hypercalcemia. Furthermore, prolonged therapy resulted in additional suppression of the PTH concentrations comparable in magnitude to that reported following intravenous calcitriol therapy and was associated with a mild degree of hypercalcemia similar to that which occurs with intravenous therapy. Euparathyroidism was achieved in 25{\%} of the patients by 15 months of treatment. In conclusion, secondary hyperparathyroidism can be effectively controlled with combined oral therapy without significant hypercalcemia in selected patients with end-stage renal failure. This salutary effect may result from direct actions of 1,25(OH)2D on the parathyroid gland and/or gastrointestinal tract, or from an overall action of combined treatment to restore calcium homeostasis.",
author = "Leigh Quarles and Davidai, {G. A.} and Schwab, {S. J.} and Bartholomay, {D. W.} and B. Lobaugh",
year = "1988",
month = "1",
day = "1",
doi = "10.1038/ki.1988.258",
language = "English (US)",
volume = "34",
pages = "840--844",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Oral calcitriol and calcium

T2 - Efficient therapy for uremic hyperparathyroidism

AU - Quarles, Leigh

AU - Davidai, G. A.

AU - Schwab, S. J.

AU - Bartholomay, D. W.

AU - Lobaugh, B.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Therapy with orally administered calcitriol often does not adequately control the biochemical manifestations of secondary hyperparathyroidism in uremic patients. This may be due to inadequate serum concentrations of 1,25(OH)2 vitamin D and/or to insufficient dietary calcium supplementation. In the present study, therefore, we examined the effect on parathyroid function of calcitriol and calcium carbonate, administered orally, in doses sufficient to normalize the serum 1,25(OH)2 vitamin D and calcium concentrations. After nine months of combined therapy, marked suppression of immunoreactive PTH occurred in the absence of hypercalcemia. Furthermore, prolonged therapy resulted in additional suppression of the PTH concentrations comparable in magnitude to that reported following intravenous calcitriol therapy and was associated with a mild degree of hypercalcemia similar to that which occurs with intravenous therapy. Euparathyroidism was achieved in 25% of the patients by 15 months of treatment. In conclusion, secondary hyperparathyroidism can be effectively controlled with combined oral therapy without significant hypercalcemia in selected patients with end-stage renal failure. This salutary effect may result from direct actions of 1,25(OH)2D on the parathyroid gland and/or gastrointestinal tract, or from an overall action of combined treatment to restore calcium homeostasis.

AB - Therapy with orally administered calcitriol often does not adequately control the biochemical manifestations of secondary hyperparathyroidism in uremic patients. This may be due to inadequate serum concentrations of 1,25(OH)2 vitamin D and/or to insufficient dietary calcium supplementation. In the present study, therefore, we examined the effect on parathyroid function of calcitriol and calcium carbonate, administered orally, in doses sufficient to normalize the serum 1,25(OH)2 vitamin D and calcium concentrations. After nine months of combined therapy, marked suppression of immunoreactive PTH occurred in the absence of hypercalcemia. Furthermore, prolonged therapy resulted in additional suppression of the PTH concentrations comparable in magnitude to that reported following intravenous calcitriol therapy and was associated with a mild degree of hypercalcemia similar to that which occurs with intravenous therapy. Euparathyroidism was achieved in 25% of the patients by 15 months of treatment. In conclusion, secondary hyperparathyroidism can be effectively controlled with combined oral therapy without significant hypercalcemia in selected patients with end-stage renal failure. This salutary effect may result from direct actions of 1,25(OH)2D on the parathyroid gland and/or gastrointestinal tract, or from an overall action of combined treatment to restore calcium homeostasis.

UR - http://www.scopus.com/inward/record.url?scp=0024269613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024269613&partnerID=8YFLogxK

U2 - 10.1038/ki.1988.258

DO - 10.1038/ki.1988.258

M3 - Article

VL - 34

SP - 840

EP - 844

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -